VYGR - ボイジャ―・セラピュ―ティクス （Voyager Therapeutics Inc.）

CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that management will participate in the following investor conferences:

In Tuesday’s session, Voyager Therapeutics Inc. (NASDAQ:VYGR) marked $9.44 per share, up from $9.07 in the previous session. While Voyager Therapeutics Inc. has overperformed by 4.08%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VYGR rose by 234.75%, with highs and lows ranging from $10.81 to […]

The overall stock market may be demonstrating resilience, but as uncertainty continues to run high, stocks have only made a modest, partial recovery. However, this works to your advantage, as many stocks remain at low prices, including the best stocks to buy for less than $25 per share. Although investors are starting to wager on a 2023 pivot on interest rates by the Federal Reserve , inflation remains at multi-decade highs. The Fed could still decide to keep raising rates until inflation starts to ease. With this, there may be a round or two of additional volatility before the bull market returns. Yet if you focus on high-quality lower-priced stocks, this isn’t a major concern. These names can handle additional volatility. Some of these could perform strongly with secular growth catalysts even if the overall stock market stays in a slump throughout the year. So, what are the best stocks to buy for less than $25 per share? Consider these seven. Each one earns an A rating in Portfolio Grader.

Investors are taking profits on this red-hot stock this week.

In trying to deliver breakthrough, Voyager is able to ink multiple robust deals with reputable companies. Read why the Neurocrine deal signals more upside for VYGR.

Voyager Therapeutics, Inc. (NASDAQ:NASDAQ:VYGR) Q3 2022 Results Conference Call November 08, 2022 08:30 AM ET Company Participants Alfred Sandrock - Chief Executive Officer Peter…

Voyager Therapeutics press release (VYGR): Q3 GAAP EPS of $0.45 beats by $0.79.Revenue of $41.1M (+2677.0% Y/Y) beats by $32.07M.Cash, cash equivalents and marketable securities as…

- Voyager’s TRACER TM capsid platform validated by Pfizer option exercise -

- Voyager''s TRACERTM capsid platform validated by Pfizer option exercise - - Data characterizing a novel receptor and demonstrating low-dose potential further validate TRACER - - Pipeline programs…

Voyager Therapeutics (VYGR) is scheduled to announce Q3 earnings results on Tuesday, November 8th, before market open.The consensus EPS Estimate is -$0.43 (+35.8% Y/Y) and the…

Voyager Therapeutics Inc. (NASDAQ:VYGR) shares, rose in value on Friday, 06/24/22, with the stock price down by -1.37% to the previous day’s close as strong demand from buyers drove the stock to $5.76. Actively observing the price movement in the last trading, the stock closed the session at $5.84, falling within a range of $5.66 … Analysts Predict A Surge In Voyager Therapeutics Inc. (NASDAQ: VYGR)? Read More »

Voyager Therapeutics Inc. (NASDAQ:VYGR)’s traded shares stood at 0.17 million during the last session, with the company’s beta value hitting 1.12. At the close of trading, the stock’s price was $5.00, to imply an increase of 3.73% or $0.18 in intraday trading. The VYGR share’s 52-week high remains $10.60, putting it -112.0% down since that … Voyager Therapeutics Inc. (NASDAQ: VYGR) Has Advanced 11.36% In 2022; Is The Share Price Attractive Enough At $10.00? Read More »

In last trading session, Voyager Therapeutics Inc. (NASDAQ:VYGR) saw 0.44 million shares changing hands with its beta currently measuring 1.10. Company’s recent per share price level of $5.40 trading at -$0.03 or -0.55% at ring of the bell on the day assigns it a market valuation of $197.05M. That closing price of VYGR’s stock is … Voyager Therapeutics Inc. (NASDAQ:VYGR) Stock Boosted 99.26% So Far In 2022, What Analysts Expect Next? Read More »

Voyager Therapeutics has signed licensing deals with two large drug makers since we last looked in on it. Read what to know about VYGR stock here.